性产品Flibanserin女性性增强剂CAS 167933-07-5
快速详细：
产品名称：氟班色林
cas号码：167933-07-5
einecs编号：
分子式：C20H21F3N4O
分子量：390.4
内容：98％
包装：1KG /袋
外观：白色粉末
等级：药用级
用法：作为非激素治疗对绝经前性功能障碍（HSDD）患者进行研究的药物，

描述：
HSDD是女性性功能障碍最常见的形式。 HSDD被定义为持续性或复发性缺乏或不存在性幻想和性行为的欲望，导致明显的痛苦或人际关系困难，并且不被医疗，与物质有关的精神病学（例如，抑郁症） ）或其他性状况。 HSDD的原因被认为涉及许多社会，心理和生物因素，可能归因于这些因素的复杂相互作用。
应用：
一种旨在提高妇女性欲的新药物对于某些人而言是有争议的，并且被其他人热切期待，但是这是一个潜在的严重障碍。在两项临床试验中，该药物不会超过安慰剂，从而提高妇女的欲望。美国食品和药物管理局今天在其网站上公布了临床试验结果，该委员会周五将召开一次委员会会议，专家小组将投票决定是否建议批准称为氟班色林的药物。 （FDA通常遵循其专家小组的建议。）虽然用户每月使用的性能令人满意的事件数量略有增加，但检查结果的FDA工作人员称所谓的反应率不是“特别引人注目。 “ING。 “"
它被称为“小粉红色药片”，这是一种可以对治疗女性性功能障碍产生巨大影响的小片。如果被批准，它将成为市场上首例同类产品。
己烯雌酚
雌二醇苯甲酸酯
雌二醇戊酸酯
雌二醇
雄激素雌二醇
雌二醇雌二醇

Sex Product Flibanserin for Female Sexual Enhancer CAS 167933-07-5
Quick Detail:
Product Name: Flibanserin
CAS No.: 167933-07-5
EINECS No.:
Molecular formula: C20H21F3N4O
Molecular weight: 390.4
Content: 98%
Packing: 1KG/Bag
Appearance: White powder
Grade: Pharmaceutical grade
Usage: Adrug being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD)

Description:
HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related, psychiatric (e. G., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to a complex interplay of these factors.
Applications:
A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit a potentially serious snag. The drug didn't boost women's desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin. (The FDA usually follows the recommendations of its expert panels. ) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn't 'particularly compelling. 'ing. ""
It's called the 'little pink pill, ' a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it's approved, it would become the first drug of its kind on the market.the market.
Diethylstilbestrol
Estradiol Benzoate
Estradiol Valerate
Estradiol
Estradiol Cypionate
Estradiol Enanthate